Abstract
Although sorafenib has shown survival benefits in patients with hepatocellular carcinoma (HCC), many patients require discontinuation or dose reduction due to adverse events (AEs). We applied a dose escalation scheme to increase patient compliance and avoid AEs. Of 267 HCC patients treated with first-line sorafenib, 25 at increased risk of AEs, including those with advanced liver cirrhosis, a history of liver transplantation, or cytopenia, received the dose escalation scheme. They started on a reduced dose of sorafenib which increased to the standard dosage according to tolerance in each patient. We analyzed the efficacy and safety of the dose escalation scheme. Patients with risk factors showed a lower disease control rate, shorter survival, and more frequently grade 3/4 AEs. Among patients presenting risk factors, the dose scheme did not affect the efficacy of sorafenib or survival, but reduced the incidence of grade 3/4 AEs. Rates of sorafenib discontinuation and dose reduction related to AEs were also lower in the dose escalation group. Dose escalation to the standard dose of sorafenib was achieved in 16 of the 25 patients in the dose escalation group (64.0%). After 2 weeks, the dose intensity of sorafenib did not differ be...Continue Reading
References
Dec 12, 2003·Lancet·Josep M LlovetJordi Bruix
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk StrumbergSiegfried Seeber
Aug 25, 2005·Journal of Hepatology·Pietro MajnoUNKNOWN Geneva Liver Cancer Study
Oct 27, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jordi BruixUNKNOWN Practice Guidelines Committee, American Association for the Study of Liver Diseases
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Dec 20, 2008·The Lancet Oncology·Ann-Lii ChengZhongzhen Guan
Feb 28, 2009·Journal of Clinical Gastroenterology·Marcus Alexander WörnsPeter Robert Galle
May 25, 2010·Japanese Journal of Clinical Oncology·Dok Hyun YoonYoon-Koo Kang
Citations
Jun 6, 2012·PloS One·Olivier MirFrançois Goldwasser
May 13, 2014·PloS One·Hao HuZhengqiang Yang
Jul 19, 2013·Radiology·Gwang Hyeon ChoiHan Chu Lee
Aug 1, 2012·Expert Review of Anticancer Therapy·Rodolfo SaccoCarlo Bartolozzi
Jan 15, 2016·Colloids and Surfaces. B, Biointerfaces·Wang YanhuaShengmin Zhang
May 8, 2014·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Manabu MorimotoKatsuaki Tanaka
Nov 22, 2012·Journal of Cellular Physiology·Brian I CarrAntonio Di Carlo
Jan 12, 2013·Liver International : Official Journal of the International Association for the Study of the Liver·Katsutoshi SugimotoYasuharu Imai
Oct 3, 2014·Journal of Gastroenterology and Hepatology·Sangheun LeeKwang-Hyub Han
Jul 15, 2015·Future Oncology·Bruno DanieleGyörgy Bodoky
Jan 9, 2016·PloS One·Yoshiyuki WadaHideki Saitsu
Oct 1, 2014·American Journal of Clinical Oncology·Gwang Hyeon ChoiHan Chu Lee
Jun 19, 2018·PloS One·Hitomi TakadaNamiki Izumi
Feb 23, 2013·Oncology·Liliana MontellaSalvatore Del Prete
Sep 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kim A ReissDavid E Kaplan
May 6, 2020·Acta Oncologica·Tim A LabeurHeinz-Josef Klümpen
Mar 17, 2017·Targeted Oncology·Gillian M Keating
Apr 1, 2014·Hepatic Oncology·Marcus Alexander Wörns, Peter Robert Galle
Dec 15, 2018·Journal of Gastroenterology and Hepatology·Toshifumi TadaJunko Tanaka
Nov 20, 2020·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Robert J Cersosimo